Dyslipidemia and oxidative stress are causative factors for atherosclerosis changes in hemodialysis patients

B. H. V. K. Praveen Varma¹, T. Madhusudhana Rao¹*, D. S. S. K. Raju²

¹Department of General Medicine, ²Department of Biochemistry, Maharajah’s Institute of Medical Sciences, Nellimarla, Vizianagaram, Andhra Pradesh, India

Received: 20 August 2019
Accepted: 26 August 2019

*Correspondence:
Dr. T. Madhusudhana Rao,
E-mail: drtirumaladevi@gmail.com

ABSTRACT

Background: Cardiovascular disease is one of the leading cause of death in chronic kidney disease. The increased cardiovascular mortality observed in all stages of Chronic kidney disease patients. In hemodialysis cardiovascular mortality is more than 60%. In hemodialysis dyslipidemia contribute for the triggering of atherosclerosis. Endothelial dysfunction and oxidative stress are serves as main precursor for the progression of atherosclerosis. So the present study was aimed at studying lipid profile and oxidative stress in hemodialysis patients.

Methods: A cross sectional study carried out over a 2 year period in Department Nephrology and General Medicine OPD, MIMS, Vizianagaram, Andhra Pradesh, India. A total of 60 hemodialysis patients are included. In all the participants Lipid profile, SOD, MDA and Serum Nitrate was measured.

Results: There is a significantly increased levels of serum triglycerides and VLDL in hemodialysis patients when compared with Control. The HDL-C was significant Lower in hemodialysis patients when compared with control. The serum total cholesterol and LDL-C not shown any significant change. The Serum MDA and Serum Nitrate was significantly higher in hemodialysis patients compared with Control and it is statistically significant (p<0.001). Whereas the serum SOD value was significantly decreased in hemodialysis patients when compared with control and it is statistically significant (p<0.001).

Conclusion: Present study finding suggested that the incidence of atherosclerosis changes are higher in hemodialysis patients. Early detection and correction of atherosclerosis changes can help us to reducing the deleterious effects.

Keywords: Cardiovascular disease, Hemodialysis, Lipid profile, Oxidative stress
This may be a risk factor for atherosclerosis complication leading to mortality and morbidity in chronic kidney disease patients.6

Reactive Oxygen Species (ROS) are continuously produced from the routine cellular physiology.7 But derangement in the production lead to oxidative stress. Hemodialysis is pro-oxidant state. The degree of oxidative stress depends on production of free radicals and concentration of antioxidants.8 In hemodialysis patients due to oxidative stress causes lipid peroxidation and which can indirectly assay by malondialdehyde(MDA) and antioxidant status can be estimated by measuring superoxide dismutase (SOD).9

Increased oxidative stress will causes reducing availability of nitric oxide by converting into peroxynitrite, which will further cause endothelial dysfunction and subsequently shows effect on vascular function.10 All the conditions causes changes in the vascular permeability and entrance of Low density lipoprotein (LDL) into the intima. Here it is oxidized due to oxidative stress and initiates inflammatory process.11

**METHODS**

The present study is a cross sectional study carried out over a 2 year period that is from June 2017 to June 2019 in Department of Nephrology and General Medicine OPD, MIMS, Vizianagaram, Andhra Pradesh, India. Those who were hemodialysis patients and attending nephrology unit over a one year period were taken as subjects for the present study. A total of 60 patients from hemodialysis were included in this study. Patients attending nephrology unit other than hemodialysis, Patients with any debilitating illness and hemodialysis patients who did not provide inform constant were excluded. To all Participants the importance of the study and procedure to be performed were informed. Informed consent was obtained from all the participants. A questionnaire was given to all patients and detailed clinical examination was performed.

In all the participants blood pressure measured by using sphygmomanometer both systolic and diastolic blood pressure was measured based on 1st and 5th korotkoff phase. All the participants are subjected 12 lead Electrocardiography and recorded at paper speed 25mm/s and 1-mV/cm calibration.

In all these participants, blood urea was estimated by GLDH – Urease method.12 Serum creatinine was estimated by Jaffes method.13 Based on serum creatinine, estimated GFR (eGFR) was computed by the Modification of Diet in Renal Disease (MDRD).14 The serum total cholesterol and HDL-C were analyzed using cholesterol oxidase method.15,16 triglyceride assessment was estimated by glycerol kinase method, LDL-C was calculated by using Friedwald formula,17,18 serum SOD activity was estimated by Kakkar et al, method and serum MDA level was estimated by Thioarbituric acid method.19,20 Serum nitrate will be estimated by colorimetric Griess assay.21

All the data was expressed in Mean and Standard deviation (mean±SD). Statistical significance between control and cases groups Z test was performed using Microsoft Excel and SPSS software 16.0. The statistical significance was determined at 5% (p <0.05) level.

**RESULTS**

The present study was conducted at Maharajah’s Institute of medical sciences, vizianagaram, Andhra Pradesh, India. A total of 120 subjects were included in which 60 are hemodialysis patients and 60 are control.

Table 1 shows the mean age of the hemodialysis patients was 47.29 years ±10.09 Control it was 43.29 years ±10.78. As regards the sex distribution, the majority of subjects were male in hemodialysis 58% and Control56%. The diagnostic criteria like blood urea and serum creatinine were significantly higher in hemodialysis patients when compared to Control. eGFR was significantly decreased in hemodialysis patients when compared with control. In the present study systolic and diastolic blood pressure was significantly increased in hemodialysis patients compared with Control (p<0.001).

| Table 1: Demographic features and diagnostic parameters in controls and hemodialysis patients. |
|---------------------------------------------------------------|
| **Number** | **Hemodialysis patients** | **Control** |
| Age (mean±SD) years | 47.29±10.09 | 43.29±10.78 |
| Sex (males %) | 58 | 56 |
| (females%) | 42 | 44 |
| Blood urea (mg/dl) | 84.22±28.12 | 16.72±10.01** |
| Serum Creatinine (mg/dl) | 7.28±3.28 | 0.76±0.24** |
| eGFR (mL/min) | 14.57±7.69 | 98.57±8.73** |
| Blood pressure (mm Hg) | | |
| Systolic | 151.45±19.87 | 110.18±8.28** |
| Diastolic | 94.21±8.73 | 75.20±4.23** |
| Type of ECG changes | | |
| LVH | N=32 | N=0 |
| Ischemic changes | N=28 | N=0 |
| **p<0.001** |

Table 2 shows significantly increased levels of serum triglycerides and VLDL in hemodialysis patients when compared with Control. The HDL-C was significant Lower in hemodialysis patients when compared with control. The serum total cholesterol and LDL-C not shown any significant change.
In the present study serum triglycerides was significantly increased due to high production and low catabolism of triglycerides. The causes are decreased lipoprotein lipase (LPL) activity due to presence of LPL inhibitors in hemodialysis patients. In addition dialysis patients repeated use of heparin causes depletion of LPL. These factors causes decreased degradation of triglycerides rich lipoprotein like chylomicron and VLDL and causes hypertriglyceridemia. In the present study serum cholesterol was not shown significant changes in control and hemodialysis patients. Previous studies observed hypercholesterolemia with heavy proteinuria and concluded that heavy proteinuria will causes changes in the HMG COA reductase and hepatic LDL receptor. In the present study proteinuria was minimal so no change in cholesterol value. Vasilis et al, also reported no change in serum cholesterol value. In the present study serum LDL was not shown significant difference between control and hemodialysis patients elevated LDL is common in nephrotic syndrome and not a feature of hemodialysis. In the present study serum HDL was significantly decreased in hemodialysis patients compared to control. The main cause for decreased HDL is due to decreased apoprotein A-I and A-II, which are main constituents of HDL. The decreased Lecithin cholesterol acyltransferase (LCAT) and increased Cholesteryl Ester Transfer Protein (CETP) also contribute decreased serum HDL. In the present study VLDL was significantly increased due to increased CETP and decreased LPL.

In hemodialysis patients the serum MDA was significantly higher when compared with Control the main cause is continues production of free radicals. This is may be due to bio incompatibility of dialysis membrane and entry of hydrophilic compounds to the dialysate and influx of toxin from dialysate. All the factors leads activation of macrophages and produce free radicals and which causes lipid peroxidation and produces MDA. The serum SOD was significantly decreased in hemodialysis patients compared with Control the causes for decreased SOD are loss zinc and copper in dialysate fluid which act as cofactor for SOD and increased lipid peroxidation causes utilization of antioxidat enzymes. The decreased RBC life span also contribute decreased SOD level in hemodialysis patients. All the above factors contribute increased free radicals which react with nitric oxide (NO) and produce pEROXY nitrite which is an unstable molecule and it will be converted into nitrate. In the present study serum nitrate was significantly higher in hemodialysis patients when compared with control. The decreased nitric oxide causes vascular endothelial dysfunction and leads to atherosclerosis changes.

From the findings of present study, it was concluded that there is a high prevalence of dyslipidemia in hemodialysis patients. Increased triglycerides decreased HDL contribute for formation of atherosclerosis. Increased MDA, serum Nitrate and decreased SOD contribute for the progression of atherosclerosis. Early detection and correction of atherosclerosis changes can help us to reducing the deleterious effects.

**DISCUSSION**

In the present study Blood urea and serum creatinine were increased in hemodialysis patients due decreased glomerular filtration. The blood pressure also significantly increased in hemodialysis patients due to hypervolemia and uncontrolled hypertension.

The most common abnormality in hemodialysis patients is hyperlipidemia. In the present study serum triglycerides was significantly increased due to high production and low catabolism of triglycerides. The causes are decreased lipoprotein lipase (LPL) activity due to presence of LPL inhibitors in hemodialysis patients. In addition dialysis patients repeated use of heparin causes depletion of LPL. These factors causes decreased degradation of triglycerides rich lipoprotein like chylomicron and VLDL and causes hypertriglyceridemia. In the present study serum cholesterol was not shown significant changes in control and hemodialysis patients. Previous studies observed hypercholesterolemia with heavy proteinuria and concluded that heavy proteinuria will causes changes in the HMG COA reductase and hepatic LDL receptor. In the present study proteinuria was minimal so no change in cholesterol value. Vasilis et al, also reported no change in serum cholesterol value. In the present study serum LDL was not shown significant difference between control and hemodialysis patients elevated LDL is common in nephrotic syndrome and not a feature of hemodialysis. In the present study serum HDL was significantly decreased in hemodialysis patients compared to control. The main cause for decreased HDL is due to decreased apoprotein A-I and A-II, which are main constituents of HDL. The decreased Lecithin cholesterol acyltransferase (LCAT) and increased Cholesteryl Ester Transfer Protein (CETP) also contribute decreased serum HDL. In the present study VLDL was significantly increased due to increased CETP and decreased LPL.

In hemodialysis patients the serum MDA was significantly higher when compared with Control the main cause is continues production of free radicals. This is may be due to bio incompatibility of dialysis membrane and entry of hydrophilic compounds to the dialysate and influx of toxin from dialysate. All the factors leads activation of macrophages and produce free radicals and which causes lipid peroxidation and produces MDA. The serum SOD was significantly decreased in hemodialysis patients compared with Control the causes for decreased SOD are loss zinc and copper in dialysate fluid which act as cofactor for SOD and increased lipid peroxidation causes utilization of antioxidat enzymes. The decreased RBC life span also contribute decreased SOD level in hemodialysis patients. All the above factors contribute increased free radicals which react with nitric oxide (NO) and produce pEROXY nitrite which is an unstable molecule and it will be converted into nitrate. In the present study serum nitrate was significantly higher in hemodialysis patients when compared with control. The decreased nitric oxide causes vascular endothelial dysfunction and leads to atherosclerosis changes.

From the findings of present study, it was concluded that there is a high prevalence of dyslipidemia in hemodialysis patients. Increased triglycerides decreased HDL contribute for formation of atherosclerosis. Increased MDA, serum Nitrate and decreased SOD contribute for the progression of atherosclerosis. Early detection and correction of atherosclerosis changes can help us to reducing the deleterious effects.

**ACKNOWLEDGEMENTS**

The authors acknowledge the help and support provided by the Department of Nephrology, Maharajah’s institute of medical sciences, Nellimarla, Vizianagaram district, Andhra Pradesh, India.

**Funding: No funding sources**

**Conflict of interest: None declared**

**Ethical approval: The study was approved by the Institutional Ethics Committee**

---

Table 2: Comparative study of serum lipid profile in control and hemodialysis patients.

| Parameters          | Hemodialysis patients | Control       |
|---------------------|-----------------------|---------------|
| Serum Triglycerides (mg/dl) | 185.22±17.23**        | 113.8±17.83   |
| Serum Total cholesterol (mg/dl) | 172.61±21.78         | 169.26±13.17  |
| Serum HDL-C (mg/dl)   | 28.67±3.83**          | 43.52±4.26    |
| Serum LDL-C (mg/dl)   | 106.90±22.96          | 102.98±13.65  |
| Serum VLDL (mg/dl)    | 37.04±3.82**          | 22.76±3.56    |

Table 3: Comparative study of serum MDA, serum nitrate and SOD in control and hemodialysis patients.

| Parameters          | Hemodialysis | Control |
|---------------------|--------------|---------|
| MDA (nmol/ml)       | 7.21±0.64**  | 1.96±0.58 |
| Serum Nitrate(µmol/L) | 33.84±2.24  | 10.21±2.32 |
| SOD (U/ml)          | 3.24±0.78**  | 8.12±2.21 |

Table 3 shows the Serum MDA and Serum Nitrate was significantly higher in hemodialysis patients compared with Control and it is statistically significant (p<0.001). Whereas the serum SOD value was significantly decreased in hemodialysis patients when compared with control and it is statistically significant (p<0.001).
REFERENCES

1. Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol. 2006;1(1):8-18.
2. Fried LF, Shlipak MG, Crump C, Kronmal RA, Bleyer AJ, Gottdiener JS, Kuller LH, Newman AB. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol. 2003 Apr 16;41(8):1364-72.
3. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clin Cardiol Epidemiol. Preven. Hypertension. 2003;42(5):1050-65.
4. Schiffrin EL, Lipman ML, Mann JFE. Chronic kidney disease. Effects on the cardiovascular system. Circulation. 2007;116(1):85-97.
5. Altman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis. 1993;21(6):573-92.
6. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis. 2000;35(5):852-62.
7. Sandau KB, Brüne B. Up-regulation of Bcl-2 by redox signals in glomerular mesangial cells. Cell Death Differ 2000;7(1):118-25.
8. Zou AP, Cowley AW Jr, Reactive oxygen species and molecular regulation of renal oxygenation. Acta Physiol Scand. 2003;179(3):233-41.
9. Bedark K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiol. Physiol Rev. 2007;87(1):245-313.
10. Massy ZA, Nguyen-Khoa T. Oxidative stress and chronic renal failure: markers and management. J Nephrol. 2002;15(4):336-41.
11. Heitz T, Schlizig T, Krohn K. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104(22):2673-8.
12. Tiffany TO, Jansen JM, Burtis CA, Overton JB, Scott CD Enzymatic kinetic rate and end-point analyses of substrate, by use of a GeMSAEC fast analyzer. Clin Chem. 1972;18(8):829-40.
13. Bowers LD. Kinetic serum creatinine assays I. The role of various factors in determining specificity. Clin Chem. 1980;26(5):551-4.
14. Raju DSSK, Lalitha DL, Kiranmaya P. Observation of estimated GFR in the assessment of chronic kidney disease: application and practice. Asian J Pharm Clin Res. 2012;5(4):201-6.
15. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20(4):470-5.
16. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyoxyanions. J Lipid Res. 1970;11(6):583-95.
17. McGowan MW, Artiss JD, Strandbergh DR, Zak B. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem. 1983;29(3):538-42.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
19. Kakkar P, Das B, Viswanathan PN. A modified spectrophotometric assay of superoxide dismutase. Indian J Biochem Biophys. 1984;21:130-2.
20. Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chim Acta. 1978;90(1):37-43.
21. Moshage H, Kok B, Huizenga JR, Jansen PL. Nitrite and nitrate determinations in plasma: a critical evaluation. Clin chemistry. 1995;41(6):892-6.
22. Huttonen JK, Pasternack A, Vantinnen T, Ehnhom C, Nikkila EA. Lipoprotein metabolism in patients with chronic uremia. Effect of hemodialysis on serum lipoproteins and postheparin plasma triglyceride lipases. Acta Med Scand. 1978;204:211-8.
23. Cheung AK, Parker CJ, Ren K, Iverius PH. Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma. Kidney Int. 1996;49(5):1360-71.
24. Liang K, Vaziri ND. Gene expression of LDL receptor, HMG-CoA reductase, and cholesterol-7 alpha-hydroxylase in chronic renal failure. Nephrol Dial Transplant. 1997;12(7):1381-6.
25. Tsimihodimos V, Mitrogianni Z, Elisaf M. Dyslipidemia associated with chronic kidney disease. Open Cardiovasc Med J. 2011;5:41-8.
26. Raju DSSK, Lalitha DL, Kiranmaya P. A Study of Lipid Profile and Lipid Peroxidation in Chronic Kidney Disease with Special Reference to Hemodialysis. J Clinic Res Bioeth. 2013;4(1):143.
27. Vaziri ND, Deng G, Liang K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant. 1999;14(6):1462-6.
28. Guarnieri GF, Moracchiello M, Campanacci L, Ursini F, Ferri L. Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia. Kidney Int Suppl. 1978;2(2):S26-30.
29. Wesen AM. Determination of Resistin and Several Antioxidant in sera of patients with chronic renal failure. Australian J Basic and Applied Sciences. 2011;5(8):196-203.
renal patients undergoing hemodialysis. Nutr Hosp. 2011;26(6):1456-61.

31. Toborek M, Wasik T, Dróżdz M, Klin M, Mgnier-Wróbel K. Effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure. Metabolism 1992;41:1229-32.

32. Muñzel T, Just H, Harrison DG. The physiology and pathophysiology of the nitric oxide/superoxide system. In: Born GVR, Schwartz CJ (eds). Vascular Endothelium: Physiology, Pathology and Therapeutic Options. Schattauer: Stuttgart. 1997;205-20.

Cite this article as: Varma BHVKP, Rao TM, Raju DSSK. Dyslipidemia and oxidative stress are causative factors for atherosclerosis changes in hemodialysis patients. Int J Adv Med 2019;6:1383-7.